4/2
12:55 pm
nvs
Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR [Yahoo! Finance]
Low
Report
Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR [Yahoo! Finance]
4/2
11:08 am
nvs
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE-IgAN Study [Yahoo! Finance]
Low
Report
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE-IgAN Study [Yahoo! Finance]
4/1
08:04 pm
nvs
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [Yahoo! Finance]
Low
Report
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [Yahoo! Finance]
4/1
11:16 am
nvs
The Vanguard ETF Up About 28% in the Past Year That Almost Nobody Outside of Income Investors Knows [Yahoo! Finance]
Low
Report
The Vanguard ETF Up About 28% in the Past Year That Almost Nobody Outside of Income Investors Knows [Yahoo! Finance]
4/1
07:16 am
nvs
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [TheStreet.com]
Low
Report
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [TheStreet.com]
3/29
01:25 am
nvs
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% [Yahoo! Finance]
Low
Report
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% [Yahoo! Finance]
3/27
04:17 pm
nvs
Assessing Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance]
Low
Report
Assessing Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance]
3/27
12:22 pm
nvs
Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure [Yahoo! Finance]
Low
Report
Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure [Yahoo! Finance]
3/27
08:13 am
nvs
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week [MSNBC.com]
Low
Report
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week [MSNBC.com]
3/27
08:06 am
nvs
Novartis to pay up to US$2 billion for US biotech firm Excellergy [BNN Bloomberg (Canada)]
Neutral
Report
Novartis to pay up to US$2 billion for US biotech firm Excellergy [BNN Bloomberg (Canada)]
3/27
03:57 am
nvs
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion [Yahoo! Finance Canada]
Low
Report
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion [Yahoo! Finance Canada]
3/27
03:55 am
nvs
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion [Yahoo! Finance]
Low
Report
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion [Yahoo! Finance]
3/27
02:40 am
nvs
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation [Yahoo! Finance]
Low
Report
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation [Yahoo! Finance]
3/26
01:49 pm
nvs
Novartis (NVS) had its price target raised by Morgan Stanley from $143.00 to $170.00. They now have an "overweight" rating on the stock.
Low
Report
Novartis (NVS) had its price target raised by Morgan Stanley from $143.00 to $170.00. They now have an "overweight" rating on the stock.
3/23
04:43 pm
nvs
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree [Seeking Alpha]
Low
Report
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree [Seeking Alpha]
3/23
07:40 am
nvs
Is iShares International Equity Factor ETF (INTF) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is iShares International Equity Factor ETF (INTF) a Strong ETF Right Now? [Yahoo! Finance]
3/23
02:32 am
nvs
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 [Yahoo! Finance]
Low
Report
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 [Yahoo! Finance]
3/21
07:13 am
nvs
Novartis (NVS) was upgraded by Sanford C. Bernstein to "hold".
Low
Report
Novartis (NVS) was upgraded by Sanford C. Bernstein to "hold".
3/20
04:47 pm
nvs
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset [Yahoo! Finance]
Low
Report
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset [Yahoo! Finance]
3/20
07:37 am
nvs
Novartis to acquire SNV4818 from Synnovation [Yahoo! Finance]
Low
Report
Novartis to acquire SNV4818 from Synnovation [Yahoo! Finance]
3/20
06:58 am
nvs
Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance]
Low
Report
Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance]
3/20
04:52 am
nvs
Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance Canada]
Low
Report
Novartis to buy experimental breast cancer drug in up to $3 billion deal [Yahoo! Finance Canada]
3/20
02:54 am
nvs
Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline [Yahoo! Finance]
Low
Report
Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline [Yahoo! Finance]
3/20
02:36 am
nvs
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Ka Inhibitor Program [Yahoo! Finance]
Low
Report
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Ka Inhibitor Program [Yahoo! Finance]
3/17
09:11 pm
nvs
????·????????????????2036??7?3,563??????????-2026?~2036??CAGR 4.98%??? [CNET News]
Medium
Report
????·????????????????2036??7?3,563??????????-2026?~2036??CAGR 4.98%??? [CNET News]